SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
SeaStar Medical (Nasdaq: ICU) will report fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) will report fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026. A live webcast and conference call will follow at 4:30 p.m. ET / 2:30 p.m. MT, with a replay available after 7:30 p.m. ET.
Preregistration is required to join the live call; a pin and dial-in information will be provided upon registration.
Details
News Market Reaction – ICU
On Mar 19, the first trading day after this news, ICU closed 3.40% below the previous close.
Data tracked by StockTitan Argus for the Mar 19 session.
Key Figures
- Earnings date
- March 25, 2026
- Fourth quarter and year-end 2025 results release date
- Earnings call time ET
- 4:30 p.m. ET
- Scheduled start time for webcast and conference call
- Replay availability time
- 7:30 p.m. ET
- Time after which call replay becomes available
Historical Context
-
Completed required FDA SAVE Registry enrollment for QUELIMMUNE pediatric AKI safety.
-
Published positive real-world QUELIMMUNE outcomes in Pediatric Nephrology.
-
Announced CEO presentation at Noble Capital Markets virtual equity conference.
-
Outlined 2026 commercial, clinical, and regulatory milestones for QUELIMMUNE and SCD.
-
Announced Biotech Showcase 2026 presentation and investor meetings around JPM conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration. |
A replay of the call will be available after 7:30 p.m. ET and can be accessed here.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.